$ARWR News

B. Riley Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $123

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study Of Zodasiran To Treat Homozygous Familial Hypercholesterolemia

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $115

Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120

Piper Sandler Reiterates Overweight on Arrowhead Pharma, Raises Price Target to $126

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High

Arrowhead (ARWR) Soars to New High as Plozasiran Nears Expanded Commercialization

Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $115

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat

Why Arrowhead Shot Sky-High, While Chief Rival Ionis Toppled

ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval

Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR)

ARWR: SHASTA-3 and SHASTA-4 Hit on All Endpoints Including 100% Reduction in Acute Pancreatitis in High-Risk Patients

Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals (ARWR) Stock Looks Fairly Priced With Strong Sales But A Demanding 398% Run

Arrowhead Pharmaceuticals Announces Topline Results For Phase 3 SHASTA-3 And SHASTA-4 Clinical Studies Of Plozasiran In Patients With Severe Hypertriglyceridemia; Observes Deep, Durable, And Consistent Median Triglyceride Reductions Of 79% And 81% From Baseline